congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
Other/Multi
ASCO 2024 | May 31 - June 4, 2024
A phase 1/2, first-in-human study of DS-3939a in patients with advanced solid tumors: A new DXd ADC targeting TA-MUC1
Poster
Dato-DXd, T-DXd, Valemetostat
ASCO 2024 | May 31 - June 4, 2024
A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody-drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors
Oral
T-DXd
ASCO 2024 | May 31 - June 4, 2024
A randomized study comparing electronic patient-reported outcomes monitoring with routine follow-up during trastuzumab deruxtecan treatment for inoperable or metastatic breast cancer patients: PRO-DUCE study
Poster
Dato-DXd
ASCO 2024 | May 31 - June 4, 2024
Analysis of drug-related interstitial lung disease (ILD) in patients treated with datopotamab
deruxtecan (Dato-DXd)
Poster
Dato-DXd
ASCO 2024 | May 31 - June 4, 2024
Datopotamab deruxtecan (Dato-DXd) in Chinese patients with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study
Poster
Dato-DXd
ASCO 2024 | May 31 - June 4, 2024
Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab with or without platinum chemotherapy as first-line therapy for advanced non-small cell lung cancer (NSCLC); subgroup analysis from TROPION-Lung02
Oral
Dato-DXd
ASCO 2024 | May 31 - June 4, 2024
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer: Patient-reported outcomes (PROs) from the TROPION-Breast01 study
Oral
T-DXd
ASCO 2024 | May 31 - June 4, 2024
DESTINY-Breast07: Dose-expansion analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC
Poster
HER3-DXd
ASCO 2024 | May 31 - June 4, 2024
HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors
Oral
Dato-DXd
ASCO 2024 | May 31 - June 4, 2024
ICARUS-LUNG01: A phase 2 study of Dato-DXd in patients with previously treated advanced NSCLC, with sequential tissue biopsies and biomarkers analysis to predict treatment outcome